Cytokinetics
CYTK
$72.09
-7.46%
Cytokinetics Inc. is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors for debilitating diseases where muscle performance is compromised, including heart failure, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead product, MYQORZO (omecamtiv mecarbil), is an allosteric activator of cardiac myosin, positioning it as a pioneer in muscle biology with a differentiated mechanism of action. The current investor narrative centers on the commercial launch of MYQORZO for obstructive hypertrophic cardiomyopathy (HCM) and the potential expansion of its pipeline, with recent regulatory approvals and ongoing clinical trials driving both optimism and debate about market uptake and long-term revenue potential.…
CYTK
Cytokinetics
$72.09
Investment Opinion: Should I buy CYTK Today?
We rate CYTK a Buy, based on the strong analyst consensus (Strong Buy, mean 1.5) and the average target price of $109.90, implying 43% upside. The thesis is that MYQORZO's commercial launch will drive significant revenue growth, and the pipeline has multiple catalysts. The stock is suitable for investors with a high risk tolerance who believe in the product's potential.
Sign up to view all
CYTK 12-Month Price Forecast
The AI model is cautiously bullish on CYTK. The strong analyst support and positive revenue trajectory are offset by the extreme valuation and deep losses. The stock's low beta and high liquidity provide some downside protection, but the risk of a de-rating is significant. The stance would be upgraded to high confidence if MYQORZO sales accelerate, and downgraded to neutral if revenue growth stalls or clinical data disappoints.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Cytokinetics's 12-month outlook, with a consensus price target around $109.90 and implied upside of +52.5% versus the current price.
Average Target
$109.90
0 analysts
Implied Upside
+52.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$85 - $146
Analyst target range
Cytokinetics is covered by 20 analysts, with a consensus recommendation of 'Strong Buy' and a mean rating of 1.5 (where 1 is Strong Buy and 5 is Sell). The average target price is $109.90, implying an upside of 43.0% from the current price of $76.84. The target range spans from $85.00 (low) to $146.00 (high), with the high target suggesting potential for significant upside if MYQORZO sales exceed expectations and pipeline milestones are met. The low target still implies a 10.6% upside, indicating that even the most bearish analyst sees value. Recent ratings actions include upgrades from UBS (Neutral to Buy) and reaffirmations of Buy/Outperform ratings from multiple firms, reflecting positive sentiment around the commercial launch and clinical progress.
Bulls vs Bears: CYTK Investment Factors
Cytokinetics presents a high-risk, high-reward profile. The bull case rests on the successful launch of MYQORZO, a differentiated product with high gross margins, and strong analyst support with a 43% upside. However, the bear case highlights an extreme valuation (86.6x sales) that leaves no room for error, deep losses, and negative cash flow. The most important tension is whether MYQORZO's commercial uptake can justify the premium valuation; if sales disappoint, the stock could face a severe correction. Currently, the bull case has stronger evidence given the strong buy consensus and positive analyst momentum, but the risk is asymmetric to the downside.
Bullish
- Strong Buy consensus with 43% upside: 20 analysts rate CYTK a Strong Buy (mean 1.5), with an average target of $109.90, implying 43.0% upside from $76.84. The high target of $146 suggests even greater potential if MYQORZO sales exceed expectations.
- MYQORZO launch driving revenue growth: Q1 2026 revenue rose 11.26% YoY to $19.355M, driven by initial MYQORZO sales. Gross margin is high at 87.64%, reflecting the low cost of goods for biopharmaceutical products.
- Low beta offers downside protection: With a beta of 0.376, CYTK is significantly less volatile than the market, unusual for a biotech. This may appeal to risk-averse investors seeking growth with lower volatility.
- Strong liquidity with current ratio 4.53: The current ratio of 4.53 indicates robust short-term liquidity, providing a cushion to fund operations and clinical trials without immediate financing pressure.
Bearish
- Extreme valuation at 86.6x sales: The PS ratio of 86.62x is extremely elevated, implying the market is pricing in massive future revenue growth. Even a minor miss in MYQORZO uptake could trigger a sharp de-rating.
- Deep losses and negative cash flow: Q1 2026 net loss was $206M, with EPS of -$1.67. Free cash flow is -$548.9M TTM, indicating heavy reliance on external financing to sustain operations.
- Negative shareholders' equity: Debt-to-equity of -1.95 and PB of -11.56 reflect negative equity, a red flag for financial stability, though common for biotechs with accumulated losses.
- High short interest at 8.58: Short ratio of 8.58 indicates significant bearish sentiment, suggesting some investors doubt the commercial success of MYQORZO or the sustainability of the valuation.
CYTK Technical Analysis
Cytokinetics has demonstrated a robust long-term uptrend, with the stock price surging 101.94% over the past year, significantly outperforming the S&P 500's 20.48% gain. The current price of $76.84 sits at 87% of its 52-week range (low: $35.22, high: $88.31), indicating the stock is trading near its highs, which reflects strong momentum but also potential overextension. The stock's beta of 0.376 suggests it is less volatile than the broader market, which is unusual for a biotech and may appeal to risk-averse investors seeking growth with lower volatility.
Beta
0.38
0.38x market volatility
Max Drawdown
-17.4%
Largest decline past year
52-Week Range
$35-$88
Price range past year
Annual Return
+93.0%
Cumulative gain past year
| Period | CYTK Return | S&P 500 |
|---|---|---|
| 1m | -8.0% | +5.5% |
| 3m | -6.1% | +1.7% |
| 6m | +15.9% | +12.2% |
| 1y | +93.0% | +18.6% |
| ytd | +16.8% | +12.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CYTK Fundamental Analysis
Revenue for Q1 2026 was $19.355 million, a 11.26% year-over-year increase, driven by initial sales of MYQORZO and collaboration revenues. However, the company remains deeply unprofitable, with a net loss of $206.031 million in Q1 2026, translating to an EPS of -$1.67. Gross margin is high at 87.64%, reflecting the low cost of goods for biopharmaceutical products, but operating margin is -694.64% due to substantial R&D and SG&A expenses. The company's balance sheet shows a current ratio of 4.53, indicating strong short-term liquidity, but a negative debt-to-equity ratio of -1.95 suggests a complex capital structure with negative shareholders' equity. Free cash flow is deeply negative at -$548.9 million TTM, indicating heavy reliance on external financing to fund operations and clinical development.
Quarterly Revenue
$19355000.0B
2026-03
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
87.6%
Latest Quarter
Free Cash Flow
$-548921999.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CYTK Overvalued?
Given the company's negative net income, the price-to-sales (PS) ratio is the most appropriate valuation metric, currently at 86.62x, which is extremely elevated compared to the industry average. The forward PE ratio of -17.26x is also negative, reflecting expected continued losses. The EV/Sales ratio of 162.39x further underscores the premium valuation, which implies the market is pricing in substantial future revenue growth from MYQORZO and pipeline success. Historically, the PS ratio has been even higher, reaching 419.78x in Q1 2026, indicating that the current multiple, while still high, has compressed significantly, possibly due to increased revenue from product sales.
PE
-9.7x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-11.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are substantial. The company is deeply unprofitable, with a Q1 2026 net loss of $206M and EPS of -$1.67. Free cash flow is -$548.9M TTM, indicating a cash burn rate that requires frequent capital raises, which could dilute shareholders. The negative debt-to-equity ratio of -1.95 and negative shareholders' equity highlight a fragile balance sheet, though the current ratio of 4.53 provides some short-term liquidity. Revenue concentration is high, as MYQORZO is the primary commercial product, and any setback in its launch would severely impact the financials.
FAQ
The key risks are: 1) Financial: Deep losses and negative cash flow, requiring dilutive financing. 2) Valuation: Extreme PS ratio of 86.6x leaves no room for error. 3) Competitive: Other HCM treatments could erode market share. 4) Regulatory: Clinical trial failures or reimbursement issues. The most severe risk is a sales miss, which could trigger a de-rating to the 52-week low of $35.22, a -54% decline.
The 12-month forecast is bullish, with a base case target of $90-110 (50% probability), a bull case of $110-146 (30% probability), and a bear case of $60-85 (20% probability). The most likely scenario is the base case, where MYQORZO sales grow steadily and the stock reaches the average analyst target of $109.90. The key assumption is that MYQORZO achieves commercial success without major setbacks.
CYTK is overvalued based on traditional metrics, with a PS ratio of 86.6x, far above the industry average. However, this is typical for a biotech with a promising product. The market is pricing in substantial future revenue growth from MYQORZO. The stock is trading at a premium to its own history, but the PS ratio has compressed from 419.78x in Q1 2026, suggesting improving fundamentals. Whether it is overvalued depends on your view of MYQORZO's peak sales potential.
CYTK is a good buy for investors with a high risk tolerance who believe in MYQORZO's commercial potential. The stock has a Strong Buy consensus with a 43% upside to the average target of $109.90. However, the extreme valuation (86.6x sales) and deep losses mean that any disappointment could lead to a sharp decline. It is not suitable for conservative investors. If you can stomach volatility and have a long-term horizon, it could be a rewarding investment.
CYTK is better suited for long-term investment, given its high volatility and speculative nature. The low beta of 0.376 suggests less market correlation, but the stock can still swing wildly on news. Short-term trading is risky due to the high valuation and binary events like earnings and clinical data. A minimum holding period of 3-5 years is recommended to allow MYQORZO to reach its full potential and for the pipeline to mature.